Skip to content
Dose Brief
Menu
No. 264 here · Grade C

NexLife review

NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo).

Visit NexLife Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the score.

On the record

The FDA issued a warning letter to Nexlife Inc. dba Nexlife in June 2026. NexLife keeps its place here and its link is unchanged — but you should know the letter exists before you start care. Read it in the FDA's warning letter database.

Semaglutide
From $165/mo (compounded)
Tirzepatide
From $215/mo (compounded)
Coverage
Coverage not published
Brand-name
Compounded only

Prices read from NexLife's own site on . Providers change pricing without notice — check the current figure before you buy.

On the trackerNewnew to the tracker, no prior reading— New to the tracker on 1 August 2026. The published line reads From $165/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

The scorecard

NexLife scored on our six Brief Score factors. See the methodology.

Price Stability58/100
Supply Reliability75/100
Transparency72/100
Access Breadth50/100
Clinical Oversight82/100
Track Record51/100

What we like

  • LegitScript certified platform
  • Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
  • Both semaglutide and tirzepatide at competitive pricing
  • Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset

The caveats

  • State availability not publicly disclosed
  • Compounded only — no brand-name options
  • Also covers hormone optimization and longevity
  • Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
  • FDA issued Nexlife Inc. dba Nexlife a warning letter in June 2026; the letter is public in FDA's warning-letter database

The brief

Best for: Pharmacy-quality-conscious patients seeking LegitScript + NABP-certified compounded GLP-1. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo).

Ranked #264 of 546 providers we reviewed — see our #1 pick, CoreAge Rx, for comparison.

Before you decide

The questions readers ask next after reading about NexLife.

Closest here

The providers scoring nearest NexLife — the realistic shortlist if you're weighing it.

Weighing NexLife against one provider in particular? There is a full head-to-head with our top-ranked pick in CoreAge Rx vs NexLife, and every provider that outranks it is listed on the NexLife alternatives ranking.

More providers we track (24)

515 more are filed too — see every provider we track, ranked.

Pricing, states and verification reflect NexLife's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on NexLife's site. Not medical advice; see our disclosure.

← Back to all rankings